Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Scinai Immunotherapeutics Ltd. is a clinical-stage biotechnology company focused on developing immunotherapeutic products for inflammatory and autoimmune diseases. The company operates within the biopharmaceutical and immunotherapy industries, with an emphasis on biologic drugs that modulate immune responses. Scinai’s core value proposition centers on leveraging immune-regulating molecules to address conditions with significant unmet medical need.
The company’s primary programs are based on its CD24Fc platform, a recombinant fusion protein designed to regulate immune responses, and its NanoAb (VHH antibody) platform for targeted biologic therapies. Scinai does not currently generate commercial product revenue and remains primarily funded through equity financing and public capital markets. The company traces its origins to BiondVax Pharmaceuticals Ltd., founded in 2003, which initially focused on influenza vaccines before pivoting toward immunotherapy and rebranding as Scinai Immunotherapeutics Ltd. to reflect its revised strategic direction.
Business Operations
Scinai’s operations are organized around research and development activities rather than commercial sales. Its main operating segments consist of preclinical and clinical-stage drug development programs, with expenditures primarily related to laboratory research, clinical trials, regulatory preparation, and intellectual property development. The company conducts its R&D activities through in-house scientific teams and collaborations with academic institutions and contract research organizations.
The company’s lead asset, CD24Fc, has been evaluated in multiple indications, including inflammatory and autoimmune conditions, and has undergone clinical testing in humans. In addition, Scinai develops NanoAb-based biologics, which are derived from camelid single-domain antibodies and designed for stability and tissue penetration. Operations are conducted primarily through the parent entity, Scinai Immunotherapeutics Ltd., with no material revenue-generating subsidiaries reported in public filings.
Strategic Position & Investments
Scinai’s strategic focus is on advancing its immunotherapy pipeline toward later-stage clinical development while seeking strategic partnerships to support funding and commercialization. Growth initiatives include expanding the therapeutic applications of CD24Fc and advancing NanoAb candidates into clinical evaluation. The company has stated that it intends to pursue out-licensing or collaboration opportunities with larger pharmaceutical companies as part of its long-term strategy.
Historically, Scinai’s most significant strategic investment was the transition away from vaccine development and the reallocation of capital toward immunomodulatory biologics. No major acquisitions have been disclosed in recent public filings, and the company’s investment strategy remains centered on internal R&D rather than portfolio diversification. Data inconclusive based on available public sources regarding any material joint ventures or late-stage strategic investments beyond disclosed research collaborations.
Geographic Footprint
Scinai Immunotherapeutics Ltd. is headquartered in Israel, where its primary research and corporate operations are based. The company maintains a presence in the United States through its public listing on the Nasdaq Capital Market, which facilitates access to international investors and capital markets.
Operationally, Scinai’s activities are concentrated in Israel, with clinical trials, regulatory interactions, and investor outreach extending into North America and Europe as required for development programs. The company does not report manufacturing or commercial infrastructure in other regions, and its global footprint remains limited to R&D and capital market engagement.
Leadership & Governance
Scinai is led by an executive team with experience in biotechnology development, regulatory affairs, and capital markets. The leadership emphasizes capital discipline, scientific validation, and partnership-driven growth as core elements of its governance philosophy. Strategic decision-making is overseen by a board of directors with backgrounds in life sciences and public company governance.
Key executives include:
- Adi Dar – Chief Executive Officer
- Dr. Yochi Slonim – Chief Scientific Officer
- Shlomo Gadot – Chairman of the Board
- Ran Raban – Chief Financial Officer
The company’s governance structure aligns with Israeli corporate law and U.S. public company requirements, including compliance with SEC filings and Nasdaq listing standards.